Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,297 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo, 2 tablets Clear all
Completed Phase 3 Interventional Results available

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

NCT03904498
View directory record Official record
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 4 Interventional

Opiate-Induced Tolerance & Hyperalgesia in Pain Patients

NCT00246532
View directory record Official record
Conditions
Chronic Low Back Pain, Opioid-induced Hyperalgesia
Interventions
Morphine, Placebo
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 3, 2026, 9:34 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

NCT04239014
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib, Ceralasertib, Placebo to match olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 1 Interventional

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

NCT01129258
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

NCT03548584
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
Interventions
Brexpiprazole, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 3, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pimavanserin, Placebo, Quetiapine
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 3, 2026, 9:34 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
86
States / cities
Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

NCT00620685
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, PH-797804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

NCT00803543
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women

NCT02256540
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Climara, Placebo patch, Resveratrol, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 3, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

NCT03547908
View directory record Official record
Conditions
HIV-1/HBV Co-Infection
Interventions
B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Combination With Irinotecan- Erbitux

NCT00594984
View directory record Official record
Conditions
Metastatic Colorectal Cancer (MCRC)
Interventions
Cetuximab, Irinotecan, Brivanib, Brivanib Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Louisville, Kentucky • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 3, 2026, 9:34 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

NCT04572243
View directory record Official record
Conditions
Epilepsies, Myoclonic
Interventions
Placebo, Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BMS-986020, Placebo matching with BMS-986020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years to 90 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 3, 2026, 9:34 AM EDT
Terminated Phase 4 Interventional Results available

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

NCT04650217
View directory record Official record
Conditions
Depressive Disorder
Interventions
Carbidopa/levodopa, Placebo, Exercise training, Control
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NCT02161718
View directory record Official record
Conditions
Schizophrenia, Alcohol Use Disorder
Interventions
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
58
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 3, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

NCT02216097
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 3, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

NCT04705597
View directory record Official record
Conditions
Covid19
Interventions
BGE-175, Placebo
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
50 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Mesa, Arizona • Chula Vista, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort

NCT01700959
View directory record Official record
Conditions
Cancer Malignancies
Interventions
melatonin, placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 3, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional Results available

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

NCT05218096
View directory record Official record
Conditions
Generalized Myasthenia Gravis, Myasthenia Gravis
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

NCT00553059
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dexamethasone, dronabinol, palonosetron hydrochloride, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
4
States / cities
Springfield, Missouri • Greenville, South Carolina • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 3, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 3, 2026, 9:34 AM EDT